Fierce PharmaJul 22, 2026
A U.K. coverage decision showed how eligibility rules can narrow access
In 2024, England’s health-technology body issued draft guidance supporting tirzepatide for a narrower subgroup of people with obesity than the manufacturer had proposed. The decision was tied to the National Health Service and its approach to cost and evidence. The example shows that an approved medicine and a publicly funded coverage recommendation are different decisions. Eligibility rules can set boundaries around who is included even when a treatment has been cleared for use.
